Rx License-Rx

TAB-1181

Anti-Plasmodium Compositions and Methods of Use

This invention describes methods and compositions of peptides that inhibit the binding of Plasmodium falciparum ( P. falciparum ) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each being specific for a given species of Plasmodia . For P. falciparum , the erythrocyte binding antigen (EBA-175) is the ligand of the plasmodia merozoites that interacts with the receptor glycophorin A on the surface of red blood cells. Inhibiting this ligand/receptor interaction is one method of preventing further malarial attacks and is an active area of vaccine research. This invention describes another specific peptide and antibodies that inhibit this ligand/receptor binding, thus is a potential source for vaccine development. The peptide described herein is a paralogue of EBA-175, identified as EBP2. Further, the invention includes antibodies and peptides that are specific for the claimed paralogue....

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Infectious Disease

Indication: Malaria

Modality: Biologic

Focus tags: Infectious Disease

Technology tags: Biologic, Diagnostic / Biomarker, Biomanufacturing

Mechanism:

Development stage: Early / Discovery

Patent status: Expired; Abandoned

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Infectious Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with National Institutes of Health. The practical first use case is Malaria. Public description: This invention describes methods and compositions of peptides that inhibit the binding of Plasmodium falciparum ( P. falciparum ) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Malaria

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.